Merck Sues To Stop Manufacture Of Generic Fosamax

Law360, New York (April 11, 2006, 12:00 AM EDT) -- In a move to protect its embattled market share for osteoporosis treatments, Merck and Co. Inc. has filed a lawsuit in federal court against Canadian generic drug manufacturer Apotex Inc. to stifle its generic version of Fosamax.

In the lawsuit, filed in U.S. District Court in Delaware, Merck accused Apotex of knowingly infringing nine of its patents for the drug and mirrors a number of other suits that ended last year with a decade being taken of the life of the patent.

The seeds for Merck’s...
To view the full article, register now.